XenoPort (XNPT) Posts Q3 Loss of $0.81, Misss Views
More News related to XNPT
- XenoPort (XNPT) and Astellas Pharma Announce an Application for RLS Treatment XP13512 Filed with PMDA in Japan
- Astellas and XenoPort Announce Submission of a New Drug Application in Japan Requesting PMDA Approval of ASP8825/XP13512 for Restless Legs Syndrome
- CORRECTING and REPLACING GlaxoSmithKline and XenoPort Announce Extension of GSK1838262 (XP13512) FDA Review Date to February 9, 2010
- Glaxo (GSK) and XenoPort (XNPT) Announed that U.S. FDA Has Extended the Review Date of GSK1838262/XP13512
- GlaxoSmithKline and XenoPort Announce Extension of GSK1838262 (XP13512) FDA Review Date to February 9, 2010
More News related to Earnings
- Rodman & Renshaw Upgrades Origin Agritech (SEED) to Market Outperform
- Goldman Sachs Upgrades NII Holdings (NIHD) to Buy; Resumes US$ Growth
- J.P. Morgan Upgrades Cigna (CI) to Overweight
- Longbow Research Upgrades AK Steel (AKS) to Buy
- Longbow Research Upgrades Steelcase (SCS) to Buy
XenoPort, Inc. (NASDAQ: XNPT) reports Q3 loss of $0.81, versus the analyst estimate of ($0.76). Revenue for the quarter was $400,000, which compares to the estimate of $3.84 million.
Related Categories
EarningsStocks Mentioned
+0.23Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
